Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax
Recent studies from the United States add new data to anthrax research
May 10th, 2006
Investigators in the United States have published new anthrax data. Study 1: Scientists have developed powder formulations for the nasal mucosal delivery of an anthrax vaccine. Investigators in the United States report, "Anthrax remains a serious threat worldwide as a bioterrorism agent. A second-generation anthrax vaccine currently under clinical evaluation consists of a recombinant protective antigen (rPA) of Bacillus anthracis. We have previously demonstrated that complete protection against inhalational anthrax can be achieved in a rabbit model, by intranasal delivery of a powder rPA formulation. We describe the preformulation and...
Source: Vaccine Weekly (2006-05-10)
|
